Table 3 Results of a 52-week Monotherapy Trial in Adults with Type 2 Diabetes Mellitus a Figure 3 Mean HbA 1c for Adult Patients with Type 2 Diabetes Mellitus who Completed the 52-week Trial and for the Last Observation Carried Forward (LOCF, intent-to-treat) data at Week 52 (Monotherapy) Combination Therapy Add-on to Metformin In this 26-week trial, 1,091 adult patients with type 2 diabetes mellitus were randomized to liraglutide injection 0.6 mg, liraglutide injection 1.2 mg, liraglutide injection 1.8 mg, placebo, or glimepiride 4 mg (one-half of the maximal approved dose in the United States), all as add-on to metformin
How GLP-1 pharmacokinetics shape your timing decision Understanding why timing matters requires understanding how these medications move through your body
220, 24 Aug
Temperature fluctuations, light exposure, and repeated needle punctures gradually compromise the medication's chemical structure
Colonic delivery of -linolenic acid by an advanced nutrient delivery system prolongs glucagon-like peptide-1 secretion and inhibits food intake in mice
Thoroughly Reading Your Policy Don't underestimate the power of your insurance policy document
